Tetraphase Pharmaceuticals (TTPH) Posts Earnings Results, Misses Expectations By $0.02 EPS

Tetraphase Pharmaceuticals (NASDAQ:TTPH) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.02), Morningstar.com reports. The business had revenue of $1.15 million during the quarter, compared to the consensus estimate of $2.09 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.

Shares of TTPH traded down $0.08 on Friday, reaching $2.17. The stock had a trading volume of 808,354 shares, compared to its average volume of 678,728. The stock has a market cap of $118.93 million, a PE ratio of -0.83 and a beta of 2.67. Tetraphase Pharmaceuticals has a 12-month low of $2.01 and a 12-month high of $6.97.

A number of equities research analysts have recently weighed in on TTPH shares. B. Riley lifted their price objective on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 11th. WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Thursday, September 6th. Piper Jaffray Companies cut their price objective on Tetraphase Pharmaceuticals to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, October 11th. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.16.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in Tetraphase Pharmaceuticals by 3.4% during the third quarter. BlackRock Inc. now owns 4,316,258 shares of the biopharmaceutical company’s stock valued at $11,914,000 after buying an additional 143,944 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Tetraphase Pharmaceuticals by 20.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,200,413 shares of the biopharmaceutical company’s stock valued at $7,855,000 after buying an additional 367,672 shares during the last quarter. Northern Trust Corp raised its stake in Tetraphase Pharmaceuticals by 3.5% during the second quarter. Northern Trust Corp now owns 1,060,816 shares of the biopharmaceutical company’s stock valued at $3,787,000 after buying an additional 36,115 shares during the last quarter. Acadian Asset Management LLC raised its stake in Tetraphase Pharmaceuticals by 937.7% during the third quarter. Acadian Asset Management LLC now owns 433,478 shares of the biopharmaceutical company’s stock valued at $1,196,000 after buying an additional 391,704 shares during the last quarter. Finally, UBS Group AG purchased a new position in Tetraphase Pharmaceuticals during the first quarter valued at $1,130,000. Institutional investors and hedge funds own 41.02% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://sportsperspectives.com/2018/11/10/tetraphase-pharmaceuticals-ttph-posts-earnings-results-misses-expectations-by-0-02-eps.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read More: Fundamental Analysis and Choosing Stocks

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply